{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:54:50Z","timestamp":1791298490073,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016912","name":"Merck Sharp and Dohme France","doi-asserted-by":"publisher","award":["Merck Sharp and Dohme France"],"award-info":[{"award-number":["Merck Sharp and Dohme France"]}],"id":[{"id":"10.13039\/100016912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Treatment landscape in metastatic lung cancer has progressed quickly over the last decade, mainly due to immunotherapies and targeted therapies. This study aimed to describe changes in costs associated with metastatic lung cancer in France.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A cohort of patients identified between 2013 and 2021 with lung cancer and a marker of metastases (ICD-10 code or reimbursement for Bevacizumab or Pemetrexed) was built from the French claims database. Healthcare resource use was described each year. The trend in total mean monthly costs (MMC) expressed in gross price over the study period was studied using Joinpoint software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between 2013 and 2021, 147,760 metastatic lung cancer patients were identified (men :66.5%, median age: 66 years). The annual cost for all patients increased from 611,074,408\u20ac in 2013 (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200924,595) to 1,308,745,922\u20ac in 2021 (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200940,321). The MMC per patient decreased from 2013 to 2015 (from 5,853\u20ac to 4,895\u20ac), by 9.37% per year (95%CI: -17.30; -0.69), then stabilized (0.90%; 95%CI: -0.84; 2.66). An increase in drug acquisition MMC in the same proportions as the decrease in full hospitalization MMC was observed, excluding 2020.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although the global cost of metastatic lung cancer management has increased, the MMC per patient has not notably surged between 2013 and 2021. Drug acquisition MMC increase was offset by reduced full hospitalization MMC (excluding 2020), resulting in no significant uptrend. These results suggest that the global management cost increase is mainly driven by epidemiological and demographic factors. This highlights the importance of continued investment in prevention and in therapeutic innovations that may improve outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10198-025-01864-6","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T11:03:15Z","timestamp":1762945395000},"page":"881-891","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2021: an observational study from the French national health data system"],"prefix":"10.1007","volume":"27","author":[{"given":"Christos","family":"Chouaid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse","family":"Marchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Apert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Bensimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Guimard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"N\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9478-5464","authenticated-orcid":false,"given":"Manon","family":"Belhassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"de Pouvourville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"1864_CR1","unstructured":"Institut national du: cancer.: Panorama des cancers en France (2023)"},{"key":"1864_CR2","unstructured":"Sant\u00e9, P., France, Francim, H.C.L., Cancer, I.N.: Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine de 1990 \u00e0 2018- Volume 1 Tumeurs solides. (2019)"},{"issue":"1","key":"1864_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.rmra.2021.11.038","volume":"14","author":"D Debieuvre","year":"2022","unstructured":"Debieuvre, D., Locher, C., Falchero, L., Duval, Y., Molinier, O., Morel, H., et al.: Vingt Ans d\u2019\u00e9pid\u00e9miologie des cancers broncho-pulmonaires diagnostiqu\u00e9s Dans les h\u00f4pitaux non-universitaires fran\u00e7ais, l\u2019\u00e9tude KBP-2020-CPHG compar\u00e9e aux \u00e9ditions 2000 et 2010. Revue des. Maladies Respiratoires Actualit\u00e9s 14(1), 24\u201325 (2022)","journal-title":"Revue des. Maladies Respiratoires Actualit\u00e9s"},{"key":"1864_CR4","unstructured":"Institut National du Cancer: Recommandations professionnelles Cancer du poumon non \u00e0 petites cellules, Formes localis\u00e9es non op\u00e9rables, localement avanc\u00e9es et m\u00e9tastatiques. (2010)"},{"issue":"18","key":"1864_CR5","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","volume":"363","author":"EL Kwak","year":"2010","unstructured":"Kwak, E.L., Bang, Y.J., Camidge, D.R., Shaw, A.T., Solomon, B., Maki, R.G., et al.: Anaplastic lymphoma kinase Inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363(18), 1693\u20131703 (2010)","journal-title":"N. Engl. J. Med."},{"key":"1864_CR6","first-page":"1497","volume-title":"EGFR Mutations in Lung Cancer: Correlation with Clinical Response To Gefitinib Therapy","author":"JG Paez","year":"2004","unstructured":"Paez, J.G., J\u00e4nne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., et al.: EGFR Mutations in Lung Cancer: Correlation with Clinical Response To Gefitinib Therapy, vol. 304, pp. 1497\u20131500. Science, New York, NY (2004). 5676"},{"key":"1864_CR7","unstructured":"Assurance Maladie: Am\u00e9liorer la qualit\u00e9 du syst\u00e8me de sant\u00e9 et maitriser les d\u00e9penses - Propositions de l\u2019Assurance Maladie pour 2018. (2017)"},{"key":"1864_CR8","unstructured":"M\u00e9decins du monde: M\u00e9decins du monde d\u00e9voile une campagne choc pour d\u00e9noncer le prix des m\u00e9dicaments 2016 [Available from: https:\/\/www.medecinsdumonde.org\/fr\/actualites\/presse\/2016\/06\/13\/medecins-du-monde-devoile-une-campagne-choc-pour-denoncer-le-prix-des-medicaments"},{"key":"1864_CR9","unstructured":"Saout, C.: Pajares y Sanchez C. Prix et acc\u00e8s aux traitements m\u00e9dicamenteux innovants. (2017)"},{"key":"1864_CR10","doi-asserted-by":"crossref","unstructured":"Gentili, N., Balzi, W., Foca, F., Danesi, V., Altini, M., Delmonte, A., et al.: Healthcare costs and resource utilisation of Italian metastatic Non-Small cell lung cancer patients. Cancers ;16(3), 592 (2024)","DOI":"10.3390\/cancers16030592"},{"issue":"2","key":"1864_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.18553\/jmcp.2021.21216","volume":"28","author":"X Zhang","year":"2022","unstructured":"Zhang, X., Beachler, D.C., Masters, E., Liu, F., Yang, M., Dinh, J., et al.: Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the united States. Journal of Managed Care & Specialty Pharmacy 28(2), 255\u2013265 (2022)","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"issue":"Suppl 4","key":"1864_CR12","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","volume":"65","author":"P Tuppin","year":"2017","unstructured":"Tuppin, P., Rudant, J., Constantinou, P., Gastaldi-Menager, C., Rachas, A., de Roquefeuil, L., et al.: Value of a National administrative database to guide public decisions: From the systeme National d\u2019information interregimes de l\u2019assurance maladie (SNIIRAM) to the systeme National des Donnees de Sante (SNDS) in France. Rev. Epidemiol. Sante Publique. 65(Suppl 4), S149\u2013S67 (2017)","journal-title":"Rev. Epidemiol. Sante Publique"},{"key":"1864_CR13","unstructured":"Institut national de la statistique et des \u00e9tudes \u00e9conomiques (Insee): Tableaux de l\u2019\u00e9conomie fran\u00e7aise. Edition 2020 2020 [Available from: https:\/\/www.insee.fr\/fr\/statistiques\/4277705?sommaire=4318291"},{"issue":"3","key":"1864_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","volume":"19","author":"HJ Kim","year":"2000","unstructured":"Kim, H.J., Fay, M.P., Feuer, E.J., Midthune, D.N.: Permutation tests for joinpoint regression with applications to cancer rates. Stat. Med. 19(3), 335\u2013351 (2000)","journal-title":"Stat. Med."},{"key":"1864_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.vhri.2022.07.007","volume":"33","author":"M Yousefi","year":"2023","unstructured":"Yousefi, M., Jalilian, H., Heydari, S., Seyednejad, F., Mir, N.: Cost of lung cancer: A systematic review. Value in Health Regional Issues 33, 17\u201326 (2023)","journal-title":"Value in Health Regional Issues"},{"key":"1864_CR16","unstructured":"Assurance Maladie: Am\u00e9liorer la qualit\u00e9 du syst\u00e8me de sant\u00e9 et maitriser les d\u00e9penses - Propositions de l\u2019assurance maladie pour 2022. (2021)"},{"issue":"1","key":"1864_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/1759-7714.13616","volume":"12","author":"A Buja","year":"2021","unstructured":"Buja, A., Rivera, M., De Polo, A., Brino, E.D., Marchetti, M., Scioni, M., et al.: Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model. Thorac. Cancer. 12(1), 13\u201320 (2021)","journal-title":"Thorac. Cancer."},{"key":"1864_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-023-01295-2","author":"N Jovanoski","year":"2023","unstructured":"Jovanoski, N., Abogunrin, S., Di Maio, D., Belleli, R., Hudson, P., Bhadti, S., et al.: Systematic Literature Review to Identify Cost and Resource Use Data in Patients with Early-Stage Non-small Cell Lung Cancer (NSCLC). PharmacoEconomics (2023). https:\/\/doi.org\/10.1007\/s40273-023-01295-2","journal-title":"PharmacoEconomics"},{"issue":"20 Suppl","key":"1864_CR19","first-page":"S439","volume":"24","author":"B Korytowsky","year":"2018","unstructured":"Korytowsky, B., Radtchenko, J., Nwokeji, E.D., Tuell, K.W., Kish, J.K., Feinberg, B.A.: Understanding total cost of care in advanced non-small cell lung cancer pre- and postapproval of immuno-oncology therapies. Am. J. Manag. Care. 24(20 Suppl), S439\u2013s47 (2018)","journal-title":"Am. J. Manag. Care"},{"key":"1864_CR20","unstructured":"Agence R\u00e9gionale de Sant\u00e9: Le plan triennal ONDAM 2017 [Available from: https:\/\/www.ars.sante.fr\/le-plan-triennal-ondam#:~:text=Le%20Plan%20triennal%20ONDAM%20(Objectif,r%C3%A9aliser%20d\u2019ici%20fin%202017"},{"key":"1864_CR21","unstructured":"LOI n\u00b0: -41 du 26 janvier 2016 de modernisation de notre syst\u00e8me de sant\u00e9 (1)"},{"key":"1864_CR22","unstructured":"Cour des comptes. Rapport annuel sur l\u2019application des lois de financement de la s\u00e9curit\u00e9 sociale, septembre 2013"},{"issue":"2","key":"1864_CR23","doi-asserted-by":"publisher","first-page":"2S280","DOI":"10.1016\/S1877-1203(21)00121-X","volume":"13","author":"V Gounant","year":"2021","unstructured":"Gounant, V., Brosseau, S., Soussi, G., Pluvy, J., Guezzour, N., Vauchier, C., et al.: Patients avec cancers thoraciques et COVID-19: Au c\u0153ur de La temp\u00eate: Patients with chest cancer and COVID-19: At the heart of the storm. Revue des. Maladies Respiratoires Actualit\u00e9s. 13(2), 2S280\u20132S91 (2021)","journal-title":"Revue des. Maladies Respiratoires Actualit\u00e9s"},{"issue":"2","key":"1864_CR24","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100078","volume":"5","author":"G Banna","year":"2020","unstructured":"Banna, G., Curioni-Fontecedro, A., Friedlaender, A., Addeo, A.: How we treat patients with lung cancer during the SARS-CoV-2 pandemic: Primum Non nocere. ESMO open 5(2), e000765 (2020)","journal-title":"ESMO open"},{"key":"1864_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.resmer.2020.100769","volume":"78","author":"N Girard","year":"2020","unstructured":"Girard, N., Greillier, L., Zalcman, G., Cadranel, J., Moro-Sibilot, D., Mazi\u00e8res, J., et al.: Proposals for managing patients with thoracic malignancies during COVID-19 pandemic. Respiratory Medicine and Research 78, 100769 (2020)","journal-title":"Respiratory Medicine and Research"},{"issue":"19","key":"1864_CR26","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1200\/JCO.20.00960","volume":"38","author":"JM Marron","year":"2020","unstructured":"Marron, J.M., Joffe, S., Jagsi, R., Spence, R.A., Hlubocky, F.J.: Ethics and resource scarcity: ASCO recommendations for the oncology community during the COVID-19 pandemic. Journal of Clinical Oncology 38(19), 2201\u20132205 (2020)","journal-title":"Journal of Clinical Oncology"},{"key":"1864_CR27","doi-asserted-by":"crossref","unstructured":"Passaro, A., Addeo, A., Von Garnier, C., Blackhall, F., Planchard, D., Felip, E., et al.: ESMO management and treatment adapted recommendations in the COVID-19 era: Lung cancer. ESMO open. 5(Suppl 3), (2020)","DOI":"10.1136\/esmoopen-2020-000820"},{"key":"1864_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.lungcan.2018.11.008","volume":"127","author":"C Chouaid","year":"2019","unstructured":"Chouaid, C., Bensimon, L., Clay, E., Millier, A., Levy-Bachelot, L., Huang, M., et al.: Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>\u200950%) metastatic squamous and non-squamous non-small cell lung cancer in France. Lung Cancer (Amsterdam Netherlands). 127, 44\u201352 (2019)","journal-title":"Lung Cancer (Amsterdam Netherlands)"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-025-01864-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-025-01864-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-025-01864-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:02:33Z","timestamp":1783692153000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-025-01864-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1864"],"URL":"https:\/\/doi.org\/10.1007\/s10198-025-01864-6","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"21 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CC reports personal fees from AstraZeneca, Boehringer Ingelheim, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen et Amgen. CM, MN and MB are full time employees of PELyon. MA, LB and VG are full time employees of MSD. GdP reports personal fees from MSD as member of the Scientific Committee of the ELO study since 2020. JYB reports research grants from Roche, AstraZeneca, MSD, BMS and GSK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}